Sac-TMT Combo Shows Promise in Gynecologic Oncology, Bolstering Kelun-Biotech Pipeline
Event summary
- Kelun-Biotech presented Phase II data at the 2026 SGO Annual Meeting for sacituzumab tirumotecan (sac-TMT) in combination with pembrolizumab for ovarian and cervical cancers.
- In ovarian cancer, the combination therapy demonstrated a median progression-free survival (PFS) of 20.9 months and a 12-month overall survival (OS) rate of 92%.
- For cervical cancer, the combination achieved a 51% objective response rate (ORR) and a median OS of 18.9 months.
- Sac-TMT is a TROP2-directed antibody-drug conjugate (ADC) licensed to MSD for global commercialization outside of Greater China.
The big picture
Kelun-Biotech's sac-TMT program represents a significant asset in the crowded ADC space, particularly given its unique bifunctional linker design and potential bystander effect. The positive Phase II data, presented in conjunction with MSD, strengthens the commercial viability of the partnership and positions sac-TMT as a potential treatment option for patients with recurrent ovarian and cervical cancers, both areas with significant unmet medical need. The licensing deal with MSD provides Kelun-Biotech with a substantial revenue stream and access to global commercialization expertise.
What we're watching
- Regulatory Path
- The positive data presented will likely accelerate discussions with regulatory bodies in both China and outside territories, but the specifics of approval pathways remain to be seen.
- Commercialization
- MSD’s execution of global commercialization efforts will be critical to the success of sac-TMT, particularly given the existing competitive landscape in oncology.
- Clinical Expansion
- The ongoing Phase III trials sponsored by MSD will determine if these early signals of efficacy translate to a registrational outcome and broader clinical adoption.
Related topics